Structural Formula (Aza06 0000 01)
Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-153
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 71288-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure (Aza06 0000 02)
Principal Display Panel – Azacitidine For Injection 100 mg Vial Label (Aza06 0000 03)
Not available.*
Principal Display Panel – Azacitidine For Injection 100 mg Carton (Aza06 0000 04)
Azacitidine for Injection is a cautionary cytotoxic agent that can be used for subcutaneous and intravenous use only. It comes in a single-dose vial containing 100 mg of azacitidine and mannitol. The usual dosage and administration instructions can be found in the prescribing information. The vial is sterile, non-pyrogenic, and preservative-free, and the container closure is not made with natural rubber. The novaplus trademark is owned by Vizient, and the product is manufactured by Meitheal Pharmaceuticals in Chicago. The storage temperature should be between 20°C and 25°C with excursions permitted between 15°C and 30°C. The text also includes numerical codes and lot numbers for inventory and traceability purposes.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
